U.S. FDA approves Daiichi Sankyos treatment for rare joint tumor

The U.S. Food and Drug Administration on Friday approved Daiichi Sankyo Co Ltds treatment for adult patients with a type of rare, non-cancerous tumor affecting joints and limbs. U.S. FDA approves Daiichi Sankyos treatment for rare joint tumor The label for the treatment, Turalio, includes a boxed warning flagging the risk of serious and potentially fatal liver injury. The decision comes months after independent experts on an advisory panel to the FDA voted in favor of Turalio as a treatment for the debilitating condition called tenosynovial giant cell tumor (TGCT).

Upload Company Info



Chemxpert Demo Video


Dataset Sample


Chemical Name

Synonyms

Molecular Formula

Molecular Weight


To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Innovator

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Market Status

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Indication

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Therapeutic Segment

To Access this information please pay by using "Pay & Download" button.

Pay & Download

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Thank you for your enquiry

Your product will be updated soon in our database


Submit Your Query



Select Any Option



Page loaded in 0.014657 seconds